Back to Journals » Cancer Management and Research » Volume 4
Current treatment options for the management of esophageal cancer
Authors Mawhinney M, Glasgow R
Received 25 June 2012
Accepted for publication 20 August 2012
Published 2 November 2012 Volume 2012:4 Pages 367—377
DOI https://doi.org/10.2147/CMAR.S27593
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Mark R Mawhinney, Robert E Glasgow
Department of Surgery, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
Abstract: In recent years, esophageal cancer characteristics and management options have evolved significantly. There has been a sharp increase in the frequency of esophageal adenocarcinoma and a decline in the frequency of squamous cell carcinoma. A more comprehensive understanding of prognostic factors influencing outcome has also been developed. This has led to more management options for esophageal cancer at all stages than ever before. A multidisciplinary, team approach to management in a high volume center is the preferred approach. Each patient should be individually assessed based on type of cancer, local or regional involvement, and his or her own functional status to determine an appropriate treatment regimen. This review will discuss management of esophageal cancer relative to disease progression and patient functional status.
Keywords: esophageal adenocarcinoma, squamous cell carcinoma, treatment regimen, disease progression, patient functional status
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.